2025-04-17T12:40:20-05:00 2024-06-30 953001179 WINDES INC 2050 MAIN ST STE 1300 IRVINE CA 92614 990 2024-01-01 953772528 PEDIATRIC CANCER RESEARCH FOUNDATION PEDI 9498596312 2151 MICHELSON DRIVE 180 IRVINE CA 92612 SCOTT ECKER TREASURER 9498596312 2025-04-02 1 1 ELEANOR A LIVINGSTON CPA MST P00226461 9498529433 2025-04-02 2024 2025-03-06 01:10:19Z DANIELLE FRAGALLA 2151 MICHELSON DRIVE 180 IRVINE CA 92612 2310027 0 X WWW.PCRF-KIDS.ORG X 1982 CA THE FOUNDATION'S MISSION IS TO IMPROVE THE CARE, QUALITY OF LIFE AND SURVIVAL RATE OF CHILDREN WITH MALIGNANT DISEASES. THE FOUNDATION RAISES FUNDS TO SUPPORT STATE-OF-THE-ART RESEARCH THAT WILL ULTIMATELY LEAD TO A CURE FOR ALL CHILDHOOD CANCERS. 16 16 0 50 0 0 4074348 1686095 0 0 49338 38609 -139194 -340355 3984492 1384349 2040951 914813 0 0 777650 478660 0 0 638699 908569 519053 3727170 1912526 257322 -528177 3305936 2928993 1575973 1738744 1729963 1190249 FUND RESEARCH TO POWER CURES THAT REDUCE THE PERCENTAGE OF CHILDREN WHO PERISH FROM CANCER UNTIL THAT NUMBER REACHES ZERO. 0 0 1193411 914813 PEDIATRIC CANCER RESEARCH ACTIVITIES - PRIMARY FUNDING SOURCE FOR RESEARCH STUDIES, STAFF & EQUIPMENT NEEDS FOR PEDIATRIC CANCER RESEARCH LABS. SEE SCHEDULE I FOR ADDITIONAL DETAIL. 1193411 1 1 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA NY AL AK AR CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NV NH NJ NM NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X DANIELLE FRAGALLA CEO 9498596312 2151 MICHELSON DRIVE 180 IRVINE CA 92612 STEVE GIUSTO PRESIDENT 1.00 X X 0 0 0 JOHN COON VICE PRESIDENT 1.00 X X 0 0 0 THOMAS BRENNAN DIRECTOR 1.00 X 0 0 0 BETH ABRAMS DIRECTOR 1.00 X 0 0 0 SUSIE BUCHAN DIRECTOR 1.00 X 0 0 0 TIM CROMWELL DIRECTOR 1.00 X 0 0 0 CHERIE DALY DIRECTOR 1.00 X 0 0 0 SCOTT ECKER TREASURER 1.00 X X 0 0 0 KEITH KOELLER DIRECTOR 1.00 X 0 0 0 ELIZABETH MCNULTY DIRECTOR 1.00 X 0 0 0 JASON O'DONNELL DIRECTOR 1.00 X 0 0 0 AMANDA SARATSIS MD DIRECTOR 1.00 X 0 0 0 JOHN VALLELY DIRECTOR 1.00 X 0 0 0 DARTH VAUGHN DIRECTOR 1.00 X 0 0 0 JOHN WEINER DIRECTOR 1.00 X 0 0 0 NICOLE WILKINS DIRECTOR 1.00 X 0 0 0 JERI WILSON EXECUTIVE DIRECTOR 40.00 X 0 0 0 DANIELLE FRAGALLA CEO (AS OF 03/2024) 40.00 X 0 0 0 0 0 0 716450 969645 28817 1686095 38609 38609 500000 500000 0 85323 716450 425678 -340355 -340355 1384349 0 0 -301746 X 824563 824563 90250 90250 208723 65153 21930 121640 227410 70986 23893 132531 2933 916 308 1709 6647 2075 698 3874 32947 10284 3462 19201 48350 10877 2435 35038 211886 47806 13710 150370 151820 30679 121141 15571 2027 3470 10074 59291 18508 6229 34554 230 115 115 903 282 95 526 8850 2183 1663 5004 OTHER PROGRAM SERVICES 15251 15251 6901 1571 2408 2922 1912526 1193411 80416 638699 933546 616421 594253 46950 121345 69831 113268 111860 0 0 999710 1574083 250000 250000 293814 259848 3305936 2928993 247474 164469 846422 965847 164181 325351 317896 283077 1575973 1738744 X 1729963 1190249 1729963 1190249 3305936 2928993 -528177 -11537 0 X 0 1 X 1 0 X 3436116 3381857 3808467 4071163 1685095 16382698 3436116 3381857 3808467 4071163 1685095 16382698 377402 16005296 8518 66 10776 25508 38609 83477 48753 52706 47304 148763 16614938 371375 0.96330 0.96120 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 INVESTMENT IN ONCOHEROES BIOSCIENCES, INC. 250000 C 250000 DEPOSITS 7570 OPERATING LEASE RIGHT-OF-USE ASSET 252278 259848 OPERATING LEASE LIABILITY 283077 283077 X 1372812 -11537 -11537 1384349 0 1384349 1912526 0 1912526 0 1912526 PART X, LINE 2: FASB ASC TOPIC 740, INCOME TAXES, REQUIRES MANAGEMENT TO EVALUATE THE TAX POSITIONS TAKEN BY THE FOUNDATION AND TO RECOGNIZE A TAX LIABILITY IF THE FOUNDATION HAS TAKEN AN UNCERTAIN POSITION THAT MORE LIKELY THAN NOT WOULD NOT BE SUSTAINED UPON EXAMINATION BY THE INTERNAL REVENUE SERVICE. MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE FOUNDATION AND HAS CONCLUDED THAT, AS OF DECEMBER 31, 2024, THERE ARE NO UNCERTAIN POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, THAT WOULD REQUIRE RECOGNITION OF A LIABILITY OR DISCLOSURE IN THE FINANCIAL STATEMENTS. THE FOUNDATION IS SUBJECT TO ROUTINE AUDITS BY THE TAXING JURISDICTIONS. THE STATUTE OF LIMITATIONS FOR FEDERAL AND CALIFORNIA PURPOSES IS GENERALLY THREE AND FOUR YEARS, RESPECTIVELY. 2024 REACHING FOR THE CURE 586459 541649 44810 3180 1212 1400 329209 AWS GOLF TOURNAMENT 70304 35070 35234 10724 10454 5 145010 139731 5279 2013 24627 1000 41859 801773 716450 85323 5193 36563 2400 381522 425678 -340355 1 NEW YORK MEDICAL COLLEGE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595 131099420 501(C)(3) 275000 0 PEDIATRIC CANCER RESEARCH FOUNDATION LABORATORY AT NEW YORK MEDICAL COLLEGE CHILDREN'S HOSPITAL OF LOS ANGELES 4650 SUNSET BLVD LOS ANGELES CA 90027 951690977 501(C)(3) 37500 0 PRECLINIAL STUDY TO TRANSLATE THERAPY USING DNA HYPOMETHYLATING AGENTS FOR PEDIATRIC HIGH GRADE GLIOMAS CHILDREN'S HOSPITAL OF LOS ANGELES 4650 SUNSET BLVD LOS ANGELES CA 90027 951690977 501(C)(3) 25000 0 PROJECT TO LEVERAGE THE POWER OF THE IMMUNE SYSTEM TO FIGHT PEDIATRIC HIGH-GRADE GLIOMA CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 25000 0 REPORTER T CELL LINE GENERATION CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 501(C)(3) 50000 0 SINGLE-CELL DISSECTING OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA DANA FARBER 450 BROOKLINE AVE BOSTON MA 02215 042263040 501(C)(3) 50000 0 PROSPECTIVE VALIDATION OF A PROGNOSTIC LIQUID BIOPSY APPROACH FOR PEDIATRIC EWING SARCOMA CASE WESTERN 10900 EUCLID AVENUE CLEVENLAND OH 44106 341018992 501(C)(3) 37500 0 USE OF MR FINGERPRINTING FOR DETERMINING RESPONSE TO IMMUNOTHERAPY IN PEDIATRIC BRAIN TUMORS CHILDREN'S HOSPITAL OF PHILADELPHIA 2716 SOUTH ST PHILADELPHIA PA 19014 231352166 501(C)(3) 30000 0 ELUCIDATING HOW NF1 LOSS COOPERATES WITH SETD2 TO DRIVE PEDIATRIC HIGH-GRADE GLIOMA FORMATION MEMORIAL SLOAN KETTERING 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 75000 0 TOWARDS CURATIVE EPIGENETIC THERAPIES OF REFRACTORY PEDIATRIC SARCOMAS UCSF 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94118 946036493 501(C)(3) 40000 0 TACL2020-004: A RISK STRATIFIED CLINICAL TRIAL FOR PATIENTS WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA STANFORD UNIVERSITY 3172 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 50000 0 TARGETING MITOCHONDRIAL PATHWAYS IN PEDIATRIC AML JOHNS HOPKINS UNIVERSITY SOM 733 N BROADWAY BALTIMORE MD 21205 520595100 501(C)(3) 50000 0 TARGETING SHP2 AS A THERAPEUTIC STRATEGY IN FUSION-NEGATIVE RHABDOMYOSARCOMA INDIANA UNIVERSITY 509 E 3RD STREET BLOOMINGTON IN 47401 356001673 501(C)(3) 30000 0 DECODING METABOLIC DEPENDENCIES OF MPNSTS AND ITS MICROENVIRONMENT HOPE FOR HENRY 2440 WISCONSIN AVE NW SUITE 201 WASHINGTON DC 20007 200244173 501(C)(3) 49563 0 REWARDING PEDIATRIC PATIENTS AND ELEVATING THEIR CARE 12 SCHOLARSHIPS 63 90250 PART I, LINE 2: ACCORDING TO ITS ESTABLISHED GUIDELINES, PCRF SUPPORTS RESEARCH INTENDED TO DEVELOP INNOVATIVE APPROACHES TO THE TREATMENT, DIAGNOSIS AND PREVENTION OF PEDIATRIC CANCER. GRANTS ARE AWARDED TO PRINCIPAL INVESTIGATORS HOLDING AN MD OR PHD DEGREE WORKING IN DOMESTIC RESEARCH INSTITUTIONS. GRANTS ARE SUBJECT TO SCIENTIFIC PEER REVIEW BY AN INDEPENDENT COMMITTEE OF ONCOLOGISTS OR SCIENTISTS AND ARE ALSO SUBJECT TO BUDGETARY CONSTRAINTS AS DETERMINED BY PCRF'S BOARD OF DIRECTORS. REVIEW CRITERIA INCLUDES: 1) THE PROBABILITY OF AN ADVANCE IN PREVENTION, DIAGNOSIS OR TREATMENT FOR THE NEAR-TERM, 2) NOVELTY OF THE CONCEPT AND STRATEGY, 3) CLARITY OF PRESENTATION, 4) EXPERIENCE AND QUALIFICATIONS OF THE INVESTIGATORS, 5) ADEQUACY OF RESOURCES AND ENVIRONMENT, AND, 6) OVERALL PLAN FOR BRINGING THE RESEARCH FINDINGS TO CLINICAL APPLICATION. FUNDING REQUESTS MUST BE CONSISTENT WITH THE OBJECTIVES OF THE PROJECT AND GENERALLY NOT INCLUDE OVERHEAD OR INDIRECT COSTS. CERTAIN GRANT PAYMENTS ARE MADE ONLY AFTER SUBMISSION AND REVIEW OF QUARTERLY REPORTS. SUBMISSION OF SCIENTIFIC RESULTS AND UPDATES MUST BE MADE ANNUALLY. X 2 24695 X DONATED AUCTION ITEMS 3 3772 FAIR MARKET VALUE X GIFT CARDS 1 350 0 1 0 PART I, COLUMN (B): THE NUMBER OF CONTRIBUTIONS IS THE NUMBER OF DONORS. FORM 990, PART VI, SECTION B, LINE 11B THE FINAL VERSION OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE AFTER THE DETAILED REVIEW IS COMPLETED BY THE FINANCIAL DIRECTOR AND THE TREASURER. THE TREASURER DISTRIBUTES A COPY OF THE FINAL VERSION OF THE FORM 990 TO THE BOARD OF DIRECTORS FOR FINAL REVIEW PRIOR TO FILING. THE RETURN IS FILED AFTER THE BOARD REVIEWS THE FORM 990. FORM 990, PART VI, SECTION B, LINE 12C ALL BOARD MEMBERS, KEY EMPLOYEES, AND MANAGEMENT ARE COVERED BY THE CONFLICT OF INTEREST POLICY. DETERMINATIONS OF CONFLICT AND REVIEW OF CONFLICT IS PERFORMED AT THESE VARIOUS LEVELS OF THE ORGANIZATION. APPROPRIATE ACTION DEPENDING ON THE CONFLICT IS TAKEN BY MANAGEMENT, KEY EMPLOYEES AND THE BOARD. DISCLOSURE FORMS ARE REQUIRED ANNUALLY BY EACH MEMBER OF THE BOARD OF DIRECTORS, KEY EMPLOYEES, AND MANAGEMENT. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE AND BOARD APPROVES COMPENSATION OF TOP MANAGEMENT. THE COMPENSATION COMMITTEE REVIEWED INDUSTRY STANDARD COMPENSATIONS. FORM 990, PART VI, SECTION C, LINE 19 THE FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. THE CONFLICT OF INTEREST POLICY AND GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 47,806. MANAGEMENT AND GENERAL EXPENSES 13,710. FUNDRAISING EXPENSES 150,370. TOTAL EXPENSES 211,886. PEDIATRIC CANCER RESEARCH FOUNDATION NEW YORK A NOT FOR PROFIT CORPORATION 2151 MICHELSON DRIVE IRVINE CA 92618 273051697 FUNDING SOURCE FOR RESEARCH NY 501(C)(3) LINE 4 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0